Noninvasive prenatal testing detected acute myeloid leukemia in paucisymptomatic pregnant patient

Abstract

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Comprehensive genome-wide analysis of routine non-invasive test data allows cancer prediction: A single-center retrospective analysis of over 85,000 pregnancies

“…Fig. 1 E) ID-11 33 12 3.59 4.43 13 no amniocentesis performed no congenital disease axillary lymph adenopathy palpable no abnormalities breast mass and axillar lymphadenopathies invasive breast carcinoma of no special type, hormone receptor-positive HER2-negative; stage II 25 cfDNA aberrations confirmed in tumor DNA (low-pass sequencing; reported in [35] ) ID-12 32 11 11.46 17.67 18 normal amniocentesis termination of pregnancy normal bone marrow punction and blood tests suggestive for acute myeloid leukemia diffuse infiltration of liver, spleen and bone marrow, suggestive for hematological malignancy acute myeloid leukemia; FAB M5 17 cfDNA aberrations confirmed in tumor DNA (FISH; reported in [40] ) ID-13 40 12 23.2 10.38 12 NA no congenital disease normal no abnormalities mass in the spleen, multiple adenopathies retroperitoneal, gastro-hepatic, gastrosplenic, pericardial and pancreatic non-Hodgkin lymphoma, diffuse large B-cell; Ann-Arbor stage II 19 cfDNA aberrations confirmed in tumor DNA (FISH; Fig. 4 ) ID-14 22 12 2.83 10.43 35 no amniocentesis performed no congenital disease normal no abnormalities mass in anterior mediastinum; adenopathies near thoracic outlet and incisura jugularis classical Hodgkin lymphoma, nodular sclerosis Hodgkin lymphoma (NSHL); Ann-Arbor stage IIA 57 cfDNA aberrations confirmed in tumor DNA (FISH; Suppl.…”